APA (7th ed.) Citation

AS, T., Z, S., AL, H., JM, M., P, I., RJ, G., . . . KT, F. (2025). Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T. JCO precision oncology, 9, e2500119. https://doi.org/10.1200/PO-25-00119

Chicago Style (17th ed.) Citation

AS, Tsao, et al. "Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T." JCO Precision Oncology 9 (2025): e2500119. https://doi.org/10.1200/PO-25-00119.

MLA (9th ed.) Citation

AS, Tsao, et al. "Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T." JCO Precision Oncology, vol. 9, 2025, p. e2500119, https://doi.org/10.1200/PO-25-00119.